⌘K
t
| TIDM | HEMO |
| Share Price | GBX 814.94-1.73% |
| Market Cap | £52.36m |
| Date | 7 Feb 2023 |
| Time | 14:30:01 |
| Category | Capital structure |
| ID | 2080P |
7 February 2023
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Admission of Shares to Official List
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has applied to the Financial Conduct Authority to admit 2 ordinary shares of 1 pence each in the Company to the Official List in relation to a historical transaction. It is expected that the shares will be admitted on or around 8 February 2023. The total issued share capital of the Company will remain 1,141,999,321 ordinary shares of 1 pence each, none of which are held in treasury.
Enquiries:
|
Hemogenyx Pharmaceuticals plc |
|
|
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
|
|
Peter Redmond, Director |
|
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
|
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
|
|
Peterhouse Capital Limited |
Tel: +44 (0)20 7469 0930 |
|
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|